Q32 Bio (QTTB) Income from Continuing Operations (2017 - 2026)
Q32 Bio's (QTTB) quarterly Income from Continuing Operations came in at 16087000.0 in Q1 2026, down 45.83% year-on-year from 29699698.24 in Q1 2025, and down 127.87% quarter-over-quarter from 57730000.0 in Q4 2025.
Q32 Bio (QTTB) Income from Continuing Operations (2017 - 2026) Analysis & Trends
Q32 Bio's Income from Continuing Operations history runs 10 years deep, the most recent figure standing at 16087000.0 for Q1 2026.
- On a quarterly basis, Income from Continuing Operations fell 45.83% year-over-year to 16087000.0 in Q1 2026; TTM through Mar 2026 was 24765000.0, a 142.45% increase from a year earlier, with the FY2025 full-year figure at 29821000.0, up 164.68% from the prior year.
- Income from Continuing Operations retreated to 16087000.0 in Q1 2026 per QTTB's latest filing, from 57730000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 92696000.0 in Q1 2022 and bottomed at 34555000.0 in Q4 2022.
- The 5-year median for Income from Continuing Operations is 13966000.0 (2023), against an average of 5150176.47.
- Across the five-year window, Income from Continuing Operations soared 8738.96% in 2022 and tumbled 1015.44% in 2025, its largest moves.
- Year by year, Income from Continuing Operations stood at 34555000.0 in 2022, then advanced by 21.48% to 27132000.0 in 2023, then soared by 47.7% to 14189000.0 in 2024, then soared by 506.86% to 57730000.0 in 2025, then plunged by 127.87% to 16087000.0 in 2026.
- Per Business Quant, the three latest QTTB Income from Continuing Operations figures stand at 16087000.0 (Q1 2026), 57730000.0 (Q4 2025), and 7389000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Q32 Bio | 225.00 Mn | 174.25 Mn | - | -16.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -16.09 Mn |
| Dec 31, 2025 | 57.73 Mn |
| Sep 30, 2025 | -7.39 Mn |
| Jun 30, 2025 | -9.49 Mn |
| Mar 31, 2025 | -11.03 Mn |
| Dec 31, 2024 | -14.19 Mn |
| Sep 30, 2024 | -17.60 Mn |
| Jun 30, 2024 | -15.53 Mn |
| Mar 31, 2024 | 1.21 Mn |
| Dec 31, 2023 | -27.13 Mn |
| Sep 30, 2023 | -13.97 Mn |
| Jun 30, 2023 | -5.81 Mn |
| Mar 31, 2023 | -6.84 Mn |
| Dec 31, 2022 | -34.56 Mn |
| Sep 30, 2022 | -31.64 Mn |
| Jun 30, 2022 | -27.94 Mn |
| Mar 31, 2022 | 92.70 Mn |
| Dec 31, 2021 | -13.47 Mn |
| Sep 30, 2021 | -30.61 Mn |
| Jun 30, 2021 | -30.50 Mn |